STREAM (Standardized Treatment Regimen of Anti-TB Drugs for Patients with MDR-TB) Stage 1 demonstrated non-inferior efficacy of a shortened regimen (the Short regimen) for rifampicin-resistant TB (RR-TB) compared to the contemporaneous WHO-recommended regimen. This regimen included moxifloxacin and clofazimine, known to cause QT prolongation, and severe prolongation was more common on the Short regimen. This study investigated risk factors for QT prolongation with the Short regimen.
Recent Abstracts
Catalyzing Support for CRVS Improvement – Examples from the Data for Health Initiative
A Guide to Designing Contextualized Civil Registration and Vital Statistics E-Learning Courses
Guide to Developing Standard Operating Procedures (SOPs) for Civil Registration Using a Case-Based…
Building Safe and Healthy Communities
Uncovering the Hidden Risks of PM 2.5 Exposure Among School-Aged Children in Jakarta
Foundations & Futures: Reimagining Public Health in the Artificial Intelligence Era
Strengthening Health Systems to Address Air Pollution in Ethiopia
Policy Brief: Childhood Blood Lead Surveillance in Indonesia – Findings and Policy Recommendations
Impact of Blue Lanes on Road Safety: Crashes, Speed and Motorcyclists’ Perceptions in…
Impacto da Faixa Azul na Segurança Viária: Sinistros, velocidade e percepções de motociclistas…